NEW YORK (GenomeWeb News) – AltheaDx today said that it will collaborate with the Nicholas Conor Institute for Pediatric Cancer Research on developing molecular diagnostic tests for pediatric cancer.
The San Diego-based firm, which is developing microarray-based genetic tests, said that the collaboration will upon its existing test for diagnosis of multiple pediatric tumor types, and expand the test beyond diagnosis to prognosis and therapeutic monitoring. It said that the goal of the alliance is to create a single genetic panel from a single biopsy that will diagnose and inform treatment.
The Nicholas Conor Institute is a San Diego-based non-profit focused on finding new diagnostics and treatments for pediatric cancer.
The partners noted that they are currently seeking funding to cover the development costs of the program.
As reported last week by GenomeWeb Daily News, AltheaDx recently raised $6 million in a Series A round of equity financing.